4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · IEX Real-Time Price · USD
-0.30 (-1.17%)
At close: May 17, 2024, 4:00 PM
-0.62 (-2.45%)
After-hours: May 17, 2024, 7:37 PM EDT

Company Description

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States.

The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema.

The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial.

In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development.

The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation.

4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics logo
Country United States
Founded 2013
IPO Date Dec 11, 2020
Industry Biotechnology
Sector Healthcare
Employees 147
CEO Dr. David H. Kirn M.D.

Contact Details

5858 Horton Street #455
Emeryville, California 94608
United States
Phone (510) 505-2680
Website 4dmoleculartherapeutics.com

Stock Details

Ticker Symbol FDMT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $23.00
CIK Code 0001650648
CUSIP Number 35104E100
ISIN Number US35104E1001
Employer ID 47-3506994
SIC Code 2836

Key Executives

Name Position
Dr. John F. Milligan Ph.D. Executive Chairman
Dr. David H. Kirn M.D. Co-Founder, Chief Executive Officer and Director
Dr. Fariborz Kamal Ph.D. President and Chief Operating Officer
Dr. Noriyuki Kasahara M.D., Ph.D. Chief Scientific Officer
Dr. Robert Y. Kim M.B.A., M.D. Chief Medical Officer
Theresa Janke Co-Founder and Chief of Staff
Uneek Mehra Chief Financial and Business Officer
Dr. Scott P. Bizily J.D., Ph.D. Chief Legal Officer and Corporate Secretary
Dr. An Song Ph.D. Chief Development Officer
Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D. Senior Vice President and Therapeutic Area Head of Pulmonology

Latest SEC Filings

Date Type Title
May 9, 2024 8-K Current Report
May 9, 2024 10-Q Quarterly Report
Apr 10, 2024 ARS Filing
Apr 10, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 10, 2024 DEF 14A Other definitive proxy statements
Apr 1, 2024 144 Filing
Feb 29, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 29, 2024 10-K Annual Report
Feb 29, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals